NYSE:BHVNBiotechs
Biohaven Obesity Trial Milestone Puts Focus On Taldefgrobep And Valuation Gap
Biohaven has completed enrollment for its Phase 2 proof of concept trial evaluating obesity drug candidate taldefgrobep alfa.
The study is assessing taldefgrobep alfa as a potential monotherapy and in combination with standard care.
The company has indicated that topline results from the trial are expected later in the year.
For investors tracking NYSE:BHVN, this update adds a fresh angle to a story often centered on its neurology pipeline. The stock closed at $9.88, with a 30 day return of...